ALNY
Companies
NASDAQ
Alnylam Pharmaceuticals Inc.
Health Care
$308.71
+$76.89 (+32.68%)
Price Chart
Overview
About ALNY
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Market Cap
$19.3B
Volume
349.1M
Avg. Volume
292.9M
P/E Ratio
-188.97949
Dividend Yield
0.00%
Employees
2.2K
Company Information
Latest News for ALNY
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
March 24, 2025
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
March 31, 2025
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
June 10, 2025
Risk & Correlation Analysis
Market Correlation
1.06
Moderate Correlation
Volatility
High (0.44)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALNY shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$19.3B
Volume349.1M
P/E Ratio-188.98
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 13, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025